Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Abstract

Diabet. Med. 29, 682–689 (2012) Aims To examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens. Methods Internet survey of 1250 physicians (600 specialists, 650 primary care physicians) who treat patients with diabetes and telephone survey of 1530 insulin‐treated patients (180 with Type 1 diabetes, 1350 with Type 2 diabetes) in China, France, Japan, Germany, Spain, Turkey, the UK or the USA. Results One third (33.2%) of patients reported insulin omission/non‐adherence at least 1 day in the last month, with an average of 3.3 days. Three quarters (72.5%) of physicians report that their typical patient does not take their insulin as prescribed, with a mean of 4.3 days per month of basal insulin omission/non‐adherence and 5.7 days per month of prandial insulin omission/non‐adherence. Patients and providers indicated the same five most common reasons for insulin omission/non‐adherence: too busy; travelling; skipped meals; stress/emotional problems; public embarrassment. Physicians reported low patient success at initiating insulin in a timely fashion and adjusting insulin doses. Most physicians report that many insulin‐treated patients do not have adequate glucose control (87.6%) and that they would treat more aggressively if not for concern about hypoglycaemia (75.5%). Although a majority of patients (and physicians) regard insulin treatment as restrictive, more patients see insulin treatment as having positive than negative impacts on their lives. Conclusions Glucose control is inadequate among insulin‐treated patients, in part attributable to insulin omission/non‐adherence and lack of dose adjustment. There is a need for insulin regimens that are less restrictive and burdensome with lower risk of hypoglycaemia.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 21

1. 1.

   Dailey GE. Early insulin: an important therapeutic strategy. Diabetes Care. 2005;28:220-221.

   Not in our library10.2337/diacare.28.1.220

2. 2.

   Davidson MB. Early insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:222-224.

   Not in our library10.2337/diacare.28.1.222

3. 3.

   Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS. Issues relating to the early or earlier use of insulin in type 2 diabetes. Practical Diabetes Int. 2003;20:63-71.

   Not in our library

4. 4.

   Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care. 2009;32:S217-S222.

   Not in our library10.2337/dc09-s314

5. 5.

   Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.

   Not in our library10.2337/dc08-9025

6. 6.

   Cramer J. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-1224.

   Not in our library10.2337/diacare.27.5.1218

7. 7.

   Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118:27S-34S.

   Not in our library10.1016/j.amjmed.2005.04.012

8. 8.

   Peyrot M, Rubin RR, Kruger D, Travis L. Correlates of insulin injection omission. Diabetes Care. 2010;33:243-248.

   Not in our library10.2337/dc09-1348

9. 9.

   Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care. 2005;28:78-83.

   Not in our library10.2337/diacare.28.1.78

10. 10.

    Morris AD, Boyle DIR, McMahon D, MacDonald TM, Newton RW. Adherence to insulin treatment, glycemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350:1505-1510.

    Not in our library10.1016/s0140-6736(97)06234-x

11. 11.

    Peyrot M, Rubin RR. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients’ cognitive framework. Patient Prefer Adherence. 2011;5:255-265.

    Not in our library10.2147/ppa.s18799

12. 12.

    Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study (DAWN). Diabetes Care. 2005;28:2673-2679.

    Not in our library10.2337/diacare.28.11.2673

13. 13.

    Rubin RR, Peyrot M. Factors associated with physician perceptions of and willingness to recommend inhaled insulin. Curr Med Res Opin. 2011;27:285-294.

    Not in our library10.1185/03007995.2010.541434

14. 14.

    Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriers. J Diabetes Complications. 2007;21:220-226.

    Not in our library10.1016/j.jdiacomp.2006.02.004

15. 15.

    Peyrot M. Psychological insulin resistance. Overcoming barriers to insulin therapy. Practical Diabetology. 2004;23:6-12.

    Not in our library

16. 16.

    Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specalists and academic generalists. Diabetes Care. 2007;30:1448-1453.

    Not in our library10.2337/dc06-2499

17. 17.

    Peyrot M, Skovlund S, Landgraf R. Epidemiology and correlates of weight worry in the multi-national Diabetes Attitudes, Wishes and Needs (DAWN) Study. Curr Med Res Opin. 2009;25:1985-1993.

    Not in our library10.1185/03007990903073654

18. 18.

    Brod M, Kongso JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18:23-32.

    Not in our library10.1007/s11136-008-9419-1

19. 19.

    Wagner TH, Heisler M, Piette JD. Prescription drug co-payments and cost-related medication underuse. Health Econ Policy Law. 2008;3:51-67.

    Not in our library10.1017/s1744133107004380

20. 20.

    Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabet Med. 2005;22:1379-1385.

    Not in our library10.1111/j.1464-5491.2005.01644.x

21. 21.

    Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35:1014-1022.

    Not in our library10.1177/0145721709345773

Cited by papers we hold 3

• Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial · 2018
  No notice
• Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) · 2017
  No notice
• Barriers and solutions to diabetes management: An Indian perspective · 2013
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.